Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

R-Tech Ueno completes Phase I single-dose trial for new VAP-1 Inhibitor RTU-1096 Japan-based pharmaceutical venture business R-Tech Ueno has completed the Phase I single-dose clinical trial for the new molecular entity RTU-1096, a vascular adhesion protein-1 (VAP-1) inhibitor having anti-inflammatory and immunomodulatory effects. Drug Research > Drug Discovery & Development > News
AbbVie acquires cancer drugmaker Pharmacyclics for $21bn AbbVie has acquired cancer drugmaker Pharmacyclics for $21bn, further strengthening its scientific and commercial presence in oncology.
News FDA grants orphan drug status for Cerulean Pharma's ovarian cancer drug CRLX101 By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted orphan drug designation for Cerulean Pharma's nanoparticle-drug conjugate (NDC), CRLX101, for the treatment of ovarian cancer.
News NeuroVive, Sanofi enter commercialization deal for Ciclomulsion in South Korea By PBR Staff Writer
NeuroVive Pharmaceutical Asia group has collaborated with Sanofi’s local affiliate for the development and commercialization of CicloMulsion in South Korea to treat reperfusion injury in cardiovascular disease.
News
Ergomed takes over medical information service provider Sound Opinion By PBR Staff Writer
UK-based Ergomed has made the strategic acquisition of Sound Opinion, one of the UK’s leading Medical Information (MI) service providers.
News Visterra, A*STAR to develop monoclonal antibody VIS513 to treat dengue By PBR Staff Writer
US-based biotechnology firm Visterra and the Drug Discovery & Development (D3) unit under the Agency for Science, Technology and Research (A*STAR), Singapore, have collaborated to further the development of VIS513, Visterra’s neutralizing antibody to treat dengue fever.
News United Therapeutics' Unituxin gets EMA marketing authorization to treat neuroblastoma By PBR Staff Writer
United Therapeutics Europe has received marketing authorisation from the European Medicines Agency (EMA) for Unituxin (dinutuximab) to treat high-risk neuroblastoma, a type of cancer that most often occurs in young children.
News

Latest News and Insight by Sector

Production & Manufacturing

AbbVie acquires cancer drugmaker Pharmacyclics for $21bn
AbbVie has acquired cancer drugmaker Pharmacyclics for $21bn, further strengthening its scientific and commercial presence in oncology.
News
Ergomed takes over medical information service provider Sound Opinion
By PBR Staff Writer
UK-based Ergomed has made the strategic acquisition of Sound Opinion, one of the UK’s leading Medical Information (MI) service providers.
News

Drug Research

Visterra, A*STAR to develop monoclonal antibody VIS513 to treat dengue
By PBR Staff Writer
US-based biotechnology firm Visterra and the Drug Discovery & Development (D3) unit under the Agency for Science, Technology and Research (A*STAR), Singapore, have collaborated to further the development of VIS513, Visterra’s neutralizing antibody to treat dengue fever.
News
R-Tech Ueno completes Phase I single-dose trial for new VAP-1 Inhibitor RTU-1096
By PBR Staff Writer
Japan-based pharmaceutical venture business R-Tech Ueno has completed the Phase I single-dose clinical trial for the new molecular entity RTU-1096, a vascular adhesion protein-1 (VAP-1) inhibitor having anti-inflammatory and immunomodulatory effects.
News

Inward Investment

PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
News
Merck in talks to acquire Cubist Pharmaceuticals for nearly $8bn
By PBR Staff Writer
New Jersey-based drug giant Merck & Co is, reportedly, in talks over a potential acquisition of antibiotics maker Cubist Pharmaceuticals for more than $8bn.
News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
News

Contract Research & Services

NeuroVive, Sanofi enter commercialization deal for Ciclomulsion in South Korea
By PBR Staff Writer
NeuroVive Pharmaceutical Asia group has collaborated with Sanofi’s local affiliate for the development and commercialization of CicloMulsion in South Korea to treat reperfusion injury in cardiovascular disease.
News
PEI funds treatment with Aubagio for relapsing remitting multiple sclerosis
Genzyme, a Sanofi company, announced that PEI Pharmacare has included Aubagio (teriflunomide) 14mg on the provincial drug formulary as a first-line oral tablet for people in the province living with relapsing remitting multiple sclerosis (RRMS).
News

Automation

Quintiles introduces new solution to meet needs of biopharmaceutical firms in Asia-Pacific
To help Asia-Pacific emerging biopharmaceutical companies achieve their growth aspirations, Quintiles today launched a new solution set tailored to meet the needs of emerging companies in the world’s most diverse and dynamic healthcare market.
News
Highland Therapeutics gets three US patents and one notice of allowance
Highland Therapeutics, a pharmaceutical company, announced that the US Patent and Trademark Office (USPTO) has issued three patents and one Notice of Allowance (NOA) for the Company’s lead products.
News

Regulatory Affairs

FDA grants orphan drug status for Cerulean Pharma's ovarian cancer drug CRLX101
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted orphan drug designation for Cerulean Pharma's nanoparticle-drug conjugate (NDC), CRLX101, for the treatment of ovarian cancer.
News
United Therapeutics' Unituxin gets EMA marketing authorization to treat neuroblastoma
By PBR Staff Writer
United Therapeutics Europe has received marketing authorisation from the European Medicines Agency (EMA) for Unituxin (dinutuximab) to treat high-risk neuroblastoma, a type of cancer that most often occurs in young children.
News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery